Hostname: page-component-cd9895bd7-7cvxr Total loading time: 0 Render date: 2024-12-23T11:32:32.340Z Has data issue: false hasContentIssue false

Pharmacotherapeutic response of DST-positive borderline patients

Published online by Cambridge University Press:  16 April 2020

VP Kontaxakis
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
M Markianos
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
C Stefanis
Affiliation:
Department of Psychiatry, University of Athens, Eginition Hospital, 74 Vas. Sophias Avenue, 11528Athens, Greece
Get access

Summary

The cases of two borderline patients are presented, dexamethasone suppression test (DST) positive and refractory to many therapeutic interventions and treated successfully with high doses of amitriptyline (225 and 200 mg/day, respectively). During the therapeutic intervention, the psychopathological condition of the patients was evaluated using Hamilton's rating scale for depression and a constructed scale based on items 11, 12 and 13 (dysphoria, anger, sense of emptiness, boredom, anhedonia) of the diagnostic interview for borderline patients.

Type
Short communication
Copyright
Copyright © Elsevier, Paris 1995

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association 3rd ed. Diagnostic and Statistical Manual of Mental Disorders Washington DC1980Google Scholar
Brown, WAJohnston, RMayfield, DThe 24-hour dexamethasone suppression test in a clinical setting. Relationship to diagnosis, symptoms, and response to treatment. Am J Psychiatry 1979; 136: 543–7CrossRefGoogle Scholar
Brown, WAShuey, IResponse to Dexamethasone and subtype of depression. Arch Gen Psychiatry 1980; 37: 747–51CrossRefGoogle ScholarPubMed
Carrol, BJThe dexamethasone suppression test for melancholia. Br J Psychiatry 1982; 140: 292–304CrossRefGoogle Scholar
Coppen, AMilly, PHarwood, JWood, KDoes the dexamethasone suppression test predict antidepressant treatment success?. Br J Psychiatry 1985; 146: 294–6CrossRefGoogle ScholarPubMed
Cowdry, RWGardner, DLPharmacotherapy of borderline personality disorder. Arch Gen Psychiatry 1988; 45: 111–9CrossRefGoogle ScholarPubMed
Gardner, DLGowdry, RWBorderline personality disorder: A research challenge. Biol Psychiatry 1989; 45: 111–9Google Scholar
Gunderson, JGPharmacotherapy for patients with Borderline personality disorder. Arch Gen Psychiatry 1986; 43: 698–700Google ScholarPubMed
Gunderson, JGKobb, JEAustin, VThe diagnostic interview for borderline patients. Am J Psychiatry 1981; 138: 896–903Google ScholarPubMed
Gunderson, JGElliot, GRThe interface between boderline personality disorder and affective disorder. Am J Psychiatry 1986; 142: 277–87Google Scholar
Hamilton, MARating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62CrossRefGoogle ScholarPubMed
Hartocolis, PTime and affects in Borderline disorders. Int J Psychoanal 1978; 59: 157–63Google Scholar
Kontaxakis, VMarkianos, MValsamatzis, GMarkidis, MKanellos, PStefanis, CMultiple neuroendocrinological responses in borderline personality disorder patients. Acta Psychiatr Scand 1987; 76: 593–7CrossRefGoogle ScholarPubMed
Nelson, JCCarolyn, MMJatlow, PIValue of the DST for predicting response of patients with major depression to hospitalization and desipramine. Am J Psychiatry 1990; 147: 1488–92Google ScholarPubMed
Pope, HGJonas, JMHundson, JJCohen, BMGunderson, JThe validity of the DSMIII borderline personality disorder: A phenomenological, family history, treatment response, and long-term follow-up study. Arch Gen Psychiatry 1983; 40: 23–30Google Scholar
Snyder, SPitt, WMCharacterizing anger in the DSMIII borderline personality disorder. Acta Psychiatr Scand 1985; 72: 464–9CrossRefGoogle Scholar
Snyder, SSajadi, CPitt, WMGoodpaster, WAIdentifying the depressive border of the borderline personality disorder. Am J Psychiatry 1982; 139: 814–7Google ScholarPubMed
Teicher, MHGlod, CAPharmacotherapy of patients with borderline personality disorder. Hosp and Community Psychiatry 1989; 40: 887–9Google ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.